Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo Financials Strong, But Shareholder Calls For Sale Of Company

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO stepping down and no R&D leader on board, as officials evaluate pipeline.

You may also be interested in...



Endo Explains HealthTronics Acquisition to Wall Street: Relationships With Urologists Are Key

Endo's pending acquisition of HealthTronics and its settlement with Impax and Sandoz over generic Opana ER removes some near-term pressure on its shares.

Endo Explains HealthTronics Acquisition to Wall Street: Relationships With Urologists Are Key

Endo's pending acquisition of HealthTronics and its settlement with Impax and Sandoz over generic Opana ER removes some near-term pressure on its shares.

Endo Branches Out With $370M Indevus Acquisition

Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel